Tuesday, July 12, 2011
Alnylam Pharmaceuticals Inc., of Cambridge, Mass., filed a clinical trial application with the Medicines and Healthcare products Regulatory Agency for a Phase I trial of ALN-PCS, an RNAi therapeutic for treating severe hypercholesteremia.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.